MICHAEL E MORRISSEY
Engineering in Boston, MA
License number
Massachusetts 13562
Issued Date
Aug 23, 1991
Type
Engineer in Training
Address
Address
Boston, MA 02135
Professional information
Pricipal At Morrissey &Amp; Company, Llc Certified Public Accountants
Position:
Principal at Morrissey & Company, LLC
Location:
Greater Boston Area
Industry:
Accounting
Work:
Morrissey & Company, LLC
since Jan 1986
-
Principal
Education:
Northeastern University 1977 - 1982
Bachelors, Business Administration
Bachelors, Business Administration
Sr. Manager Of Investigations At Emc
Position:
Sr. Manager of Investigations at EMC
Location:
Greater Boston Area
Industry:
Security and Investigations
Work:
EMC
since May 2006
-
Sr. Manager of Investigations
Education:
Univeristy of Massachusetts Amherst
Owner At Morrissey Construction
Position:
President at Morrissey Construction
Location:
Greater Boston Area
Industry:
Construction
Work:
Morrissey Construction
since Jan 1992
-
President
Owner, Morrissey &Amp; Company
Position:
Owner at Morrissey & Company
Location:
Greater Boston Area
Industry:
Accounting
Work:
Morrissey & Company
-
Owner
Education:
Northeastern University 1977 - 1982
Bachelors, Business Administration
Bachelors, Business Administration
Plastics Professional
Location:
Greater Boston Area
Industry:
Plastics
Work:
Retired and enjoying time to pursue personal interests and family
2009 - 2011
-
retired
Methods For The Identification, Assessment, And Treatment Of Patients With Proteasome Inhibition Therapy
US Patent:
2004015, Aug 12, 2004
Filed:
Dec 4, 2003
Appl. No.:
10/728055
Inventors:
George Mulligan - Lexington MA, US
Barbara Bryant - Cambridge MA, US
Michael Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew Damokosh - West Hartford CT, US
Barbara Bryant - Cambridge MA, US
Michael Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew Damokosh - West Hartford CT, US
Assignee:
Millennium Pharmaceuticals, Inc.
International Classification:
C12Q001/68, G01N033/574, A61K039/395
US Classification:
424/155100, 435/006000
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
Methods For The Identification, Assessment, And Treatment Of Patients With Proteasome Inhibition Therapy
US Patent:
2009018, Jul 16, 2009
Filed:
Dec 16, 2008
Appl. No.:
12/316756
Inventors:
George Mulligan - Lexington MA, US
Barbara M. Bryant - Cambridge MA, US
Michael P. Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew I. Damokosh - West Hartford CT, US
Barbara M. Bryant - Cambridge MA, US
Michael P. Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew I. Damokosh - West Hartford CT, US
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435 6, 435 723
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
Service Professional At Circles
Position:
Service Professional at Circles
Location:
Greater Boston Area
Industry:
Consumer Services
Work:
Circles
-
Service Professional
Education:
Endicott College 2002 - 2006
Nucleic Acid Molecules And Proteins For The Identification, Assessment, Prevention, And Therapy Of Ovarian Cancer
US Patent:
2005021, Sep 29, 2005
Filed:
Feb 4, 2005
Appl. No.:
11/050926
Inventors:
John Monahan - Walpole MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrissey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natik MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrissey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natik MA, US
Assignee:
MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
C12Q001/68, G01N033/574
US Classification:
435006000, 435007230
Abstract:
The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.
Michael Morrissey
Location:
Greater Boston Area
Industry:
Accounting